Recent Finacing
Recent Raise
BliNK Biomedical SAS develops monoclonal antibodies for oncology using IVV, ISAAC and VIVA|Screen platforms to stimulate and isolate antigen‑specific B cells and identify antibodies; HQ Lyon, UK subsidiary.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor